268 related articles for article (PubMed ID: 7907918)
41. Differential regulation by interleukin-4 and interferon-gamma of an autologous melanoma-specific cytotoxic T-cell clone and the tumor-infiltrating lymphocytes from which it was established.
Yamada T; Holmes EC; Golub SH
Cancer Commun; 1990; 2(3):113-21. PubMed ID: 2114166
[TBL] [Abstract][Full Text] [Related]
42. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells.
Schoof DD; Terashima Y; Peoples GE; Goedegebuure PS; Andrews JV; Richie JP; Eberlein TJ
Cell Immunol; 1993 Aug; 150(1):114-23. PubMed ID: 8102084
[TBL] [Abstract][Full Text] [Related]
43. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion.
Elsässer-Beile U; Wetterauer U; Schultze-Seemann W; Gallati H; Mönting JS; von Kleist S
Cancer Immunol Immunother; 1996 Feb; 42(2):93-8. PubMed ID: 8620526
[TBL] [Abstract][Full Text] [Related]
44. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
45. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
46. Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
Peyret C; Bochner BH; Lee TY; Koo AS; deKernion JB; Belldegrun A
J Surg Res; 1992 Dec; 53(6):602-9. PubMed ID: 1494294
[TBL] [Abstract][Full Text] [Related]
47. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
Facchetti P; Prigione I; Ghiotto F; Tasso P; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1996 Mar; 42(3):170-8. PubMed ID: 8640845
[TBL] [Abstract][Full Text] [Related]
48. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.
Young MR; McCloskey G; Wright MA; Pak AS
Cancer Immunol Immunother; 1994 Jan; 38(1):9-15. PubMed ID: 8299123
[TBL] [Abstract][Full Text] [Related]
49. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
Nash MA; Lenzi R; Edwards CL; Kavanagh JJ; Kudelka AP; Verschraegen CF; Platsoucas CD; Freedman RS
Clin Exp Immunol; 1998 May; 112(2):172-80. PubMed ID: 9649178
[TBL] [Abstract][Full Text] [Related]
50. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
51. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
[TBL] [Abstract][Full Text] [Related]
52. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
53. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
54. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
55. Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas.
Wang QJ; Hanada K; Yang JC
J Immunol; 2008 Sep; 181(6):3769-76. PubMed ID: 18768829
[TBL] [Abstract][Full Text] [Related]
56. [Study of cytotoxicity of recombinant interleukin-2 (rIL-2) expanded tumor infiltrating lymphocytes (TIL) in renal cell cancer].
Nishimura T; Terashima Y; Hattori T; Satoh M; Watanabe J; Kimura G; Yoshida K; Akimoto M
Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):835-40. PubMed ID: 2402104
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
58. Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70.
Yoshino I; Goedegebuure PS; Peoples GE; Lee KY; Eberlein TJ
J Immunol; 1994 Nov; 153(9):4149-58. PubMed ID: 7930618
[TBL] [Abstract][Full Text] [Related]
59. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
60. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
Cancer Immunol Immunother; 1992; 34(4):241-51. PubMed ID: 1311218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
